AUTHOR INDEX

Andersson, R. G. G. 107

Duvoisin, R. 1

Gescher, A. 191
Glisson, B. S. 89
Grunström, N. 107

Harris, A. 293

Irwin, I. 19

Jarvis, S. M. 339

Kannel, W. B. 207
Kozhechkin, S. N. 327

Lang, A. E. 51
Langston, J. W. 19

Martin, W. R. W. 77
Marton, L. J. 183
Mitchard, M. 293
Morin, R. J. 237
Mullinger, G. M. 293

Naumova, V. I. 327

Perg, S. -K. 237

Ricaurte, G. A. 19
Rosenberg, G. B. 131
Ross, W. E. 89

Selfe, S. 131
Sokolovsky, M. 285
Storm, D. R. 131
Sugrue, M. F. 145
Sytkowski, P. A. 207

Threadgill, M. D. 191

Young, J. D. 339

Zakusov, V. V. 327
Zemplényi, T. 237

AUTHOR INDEX

Andersson, R. G. G. 107

Duvoisin, R. 1

Gescher, A. 191
Glisson, B. S. 89
Grunström, N. 107

Harris, A. 293

Irwin, I. 19

Jarvis, S. M. 339

Kannel, W. B. 207
Kozhechkin, S. N. 327

Lang, A. E. 51
Langston, J. W. 19

Martin, W. R. W. 77
Marton, L. J. 183
Mitchard, M. 293
Morin, R. J. 237
Mullinger, G. M. 293

Naumova, V. I. 327

Perg, S. -K. 237

Ricaurte, G. A. 19
Rosenberg, G. B. 131
Ross, W. E. 89

Selfe, S. 131
Sokolovsky, M. 285
Storm, D. R. 131
Sugrue, M. F. 145
Sytkowski, P. A. 207

Threadgill, M. D. 191

Young, J. D. 339

Zakusov, V. V. 327
Zemplényi, T. 237

SUBJECT INDEX

Adverse drug reactions, levodopa 14, 58–66
Aging, neurodegeneration 43
Airway smooth muscle
  and asthma 121–23
  cholinergic nerves 110, 111, 113
  innervation 107–24
    species variation 113, 114
  neuronal control 108
  neuronal scheme 123
  neurotransmitters 114–17
  nonadrenergic, noncholinergic (NANC) 111, 112
    excitatory 114
    inhibitory 113
Amphetamine
  brain neurotransmitters 154–59
  dopamine 157
  food intake 154–59
  norepinephrine 156, 158
Anorectic drugs and brain neurotransmitters 154–67
Antitumor drugs, metabolism of triazene 191–202
Arterial wall
  adenylate cyclase phosphodiesterase 247, 248
  atherosclerosis susceptible 242
  cholesterol autoxidation 259, 260
  cholesteryl ester hydrolysis 256–59
    drugs affecting 258
  cholesteryl ester synthesis 253–56
    drugs affecting 255, 256
  drugs effects 249–52
    bioflavonoids 251
    pyridinolcarbamate 251
    sex differences 250, 251
  enzymes 240–49
    age 241, 243
  fatty acid synthesis 252, 253
  hypoxia 244, 245
  injury 244, 245
  lipid metabolism 252–64
  lipoprotein catabolism 264, 265
  lysosomal hydrolases 245–47
  metabolism 237–70
  oxygenation 237
  oxygen diffusion regulation 238–40
  phospholipid metabolism 262–64
    scheme 262
  prostaglandin metabolism 265–69
  sterol synthesis 253
  triglyceride metabolism 260–62
  vasa vasorum 238
Asthma, airways smooth muscle innervation 121–23
Atherogenic lifestyles 218–23
Atherosclerosis
  arterial wall enzymes 247, 248
  risk factors 207–29
Azidocalmodulin, cross-linked polypeptides 140

Benzodiazepines, ranitine interactions 308, 309
Blood pressure and cardiovascular risk 216, 217

Calmodulin
  azidolysyl derivative 137, 138
  preparation 132–34
  sensitive adenylate cyclase 138
Calmodulin-binding protein 131
  azido-calmodulin binding 134–36
  P-57 139
Calmodulin-dependent systems, photoaffinity labeling 131–41
Carbon disulfide and Parkinsonism 30–33
  mechanism of action 32, 33
Cardiovascular disease
  age and sex 212, 213
  compromised circulation 226
  familial 225
  mortality trends 207, 208
  prevention 227–29
  risk factors 208–29
  risk profile 209
Chemotherapy, DNA directed and polyamine depletion 183–89
Cholesterol autoxidation 259, 260
Cocaine 327
  pharmaceutical effects 328
Cytochrome P-450
  ranitidine interactions 297, 298, 318

Deprenyl, Parkinson's disease 66, 67
Diabetes mellitus, cardiovascular risk 217, 218
Dicarbazine
  metabolism 199
  photodecomposition 200
Diet, cardiovascular risk 222, 223
DNA topoisomerase II 89–102
  activity regulation 91
  cleavable complex formation 94
    lethal 99–101
  DNA scission 92–95
  drug–enzyme interaction 95, 96
    cytotoxicity 97–102
    factors affecting 101, 102
  lesion 96
  location 91
  primer 89–92
  structure and function 89
  supercooling 90
Dopamine
  agonists 67–70
  food intake 147, 148
  and Parkinsonism 13–15
Dopaminergic systems
  brains 51, 52
  drugs manipulating 56–70
  manipulation in Parkinson's disease 51–70
Drug interaction, ranitidine 293–319
Dystonia, PET scanning 84

Encephalitis lethargica
epidemiology 8, 9
and flu 9, 10
pathology 9

Fenfluramine
brain neurotransmitters 159–66
food intake 159–66
peripheral effects 165, 166
repeated dose effects 164, 165
6-Fluorodopa metabolism 79
Food intake, drugs affecting 145–68
Free radicals and neuronal death 22–25

GABA and food intake 151–53

H_2-receptor blockers, ranitidine interaction 295–97
Huntington's disease, PET scanning 81, 82
6-Hydroxydopamine and Parkinsonism 33, 34
5-Hydroxytryptamine
fenfluramine effects 160–63
food intake 148–50
Hypertension
arterial walls 248, 249
cardiovascular risk 215–17

Levodopa
dyskinesis 61–63
fluctuations 63–65
mechanism of action 58
Parkinson's disease 57
psychiatric disturbances 65, 66
reduced efficiency 58–60
Lipid metabolism, arterial wall 252–64
Lipoprotein
and atherosclerosis 210–15
HDL/cholesterol ratio 211
Liver blood flow, ranitidine effects 298–300

Manganese and Parkinsonism 26–30
distribution 27, 28
and dopamine 29, 30
mechanism of action 28, 29
Mazindol, brain neurotransmitters 166, 167
Menopause and cardiovascular disease 227
Methamphetamine and Parkinsonism 34–36
MPTP 36–40
mechanism of action 38
neuropathology 37, 38
neurotoxicity scheme 39, 40
structure 37

NANC (nonadrenergic, noncholinergic) neurotransmitter 114–17
excitatory 116, 117
inhibitory 115, 116
Neuronal death
covalent binding 25, 26
detoxification failure 41–43
free radicals 22–25
manganese 26–30
nigral, compensation 54, 55
Neuropeptides and food intake 153, 154
Neurotoxins and Parkinsonism 19–44
Neurotransmission
airways smooth muscle 114–17
modulation 117–21
ingestion 145–54
Norepinephrine and food intake 146, 147
Nucleosides
cell transport 340–43
inhibitors 340, 341
kinetics 340
pharmaceutical importance 339, 340
Nucleoside transporter polypeptides
azidoadenosine 354
endoglycosidase F 352, 353
identification 347–55
inhibitor 343
photoaffinity labeling 339–55
factors affecting 347
nitrobenzyl thioinosine 347–54
protein depleted erythrocyte membranes 348, 349, 351
trypsin cleavage 350

Obesity and cardiovascular risk 219
Oral contraceptives, cardiovascular risk 220, 221

Paraquat, reduction 40
Parkinson, James 1
Parkinsonism
age 7
carbon disulfide 30–32
descriptions 3, 4
first 1, 2
dopamine 13
early names 2, 3
hands 4
herbal preparations 6, 7
6-hydroxydopamine 33, 34
levodopa 14, 15
methamphetamine 34–36
mortality 7, 8
MPTP 36–41
neurotoxins 19–44
and Parkinson's disease 20, 21
postencephalitic 10
posture 5, 6
Pembrandt 3
reversibility 21, 22
Parkinson's disease
dopaminergic manipulation 51–70
etiology 55, 56
PET scanning 82–84
Photoaffinity labeling
calmodulin-dependent systems 131–41
applications 134–41
calmodulin preparations 132–34
muscarinic receptors 285–91
azido synthesis 287, 288
ligand structure 285–87
nucleoside transporter polypeptides 339–55
techniques 344
membrane damage 347
non-specific 345–47
Pirenzepine, ranitidine interaction 293, 294
Polyamine
polyamine–nucleic acid interactions 184, 185
structures 183, 184
Polyamine depletion
cell cycle effects 186
cisplatin effects 187, 188
cytotoxic agent effects 188
DNA-directed cancer chemotherapy 183–89

nitrosourea effects 185, 186
sister chromatid exchange 186
Positron emission tomography (PET)
clinical studies 81–84
methodology 77, 78
postsynaptic dopamine function 79, 80
presynaptic dopamine function 78, 79
single photon 80
Prostaglandins, arterial cell metabolism 265–69

Ranitidine
absorption effects 294–97
aminopyrine clearance 303
anesthetics 311, 312
analgesics 315, 316
antiarrhythmics 306, 307
antiasthmatics 313, 314
anticonvulsants 308, 309
antipyrine 303, 304
β-blockers 305, 306
calcium channel blockers 307, 308
dose 305
drug interactions 293–319
drug metabolism 300–305
ethanol effect 295, 296, 314
H_2-receptor blockers 295–97
metabolism interactions 297–300
non-oxidative metabolism 303
non-steroidal anti-inflammatory drugs 315
oral hypoglycemics 314, 315
oxidative enzymes 300–303
pharmacodynamics 293, 294
renal clearance 317–19
spectra 298
warfarin 310, 311
Receptors, β-adrenergic and airway smooth muscle modulation 117–21
Receptors, dopamine 52–54
nigrostriatal 53
Receptors, muscarinic
azido-reversible reaction 288–90
product characterization 290, 291
specificity 289
photoaffinity labeling 285–91
Renal clearance and ranitidine 317–19
Risk factors
classification 209–27
constitutional 210
environmental 223
prevention, cardiovascular disease 227–29
psychosocial 224

Smoking and coronary heart disease 219–21

Theophylline, ranitidine reactions 313, 314
Triazenes
antitumor activity 202
cytotoxic metabolites 195
hydrolytic ring opening 201
metabolic fate 198
metabolism 192–98
oxidative 192–97
methylation mechanism 192, 193
structures 191
Tropan derivatives 327–36
adrenomimetic 330–32
analgesic antagonism 334–36
central stimulation 330
cholinolytic 332–34
cholinomimetic 332
local anesthetics 330
pharmacological effects 328, 329

Warfarin clearance 310